Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

President Donald Trump is moving to reverse a federal push away from plastic straws, declaring that paper straws “don’t work.

On Sunday, hundreds of millions of people will tune in to potentially witness the coronation of a dynasty. As the Kansas City ...

Manchester City are reportedly set to launch moves for Bayer Leverkusen duo Florian Wirtz and Jeremie Frimpong in a ...

New North Carolina Gov. Josh Stein says more recent laws enacted by state Republicans that erode some gubernatorial ...